This is a preview of subscription content, log in via an institution to check access.
Notes
2017 euros
Reference
Astrugue C, et al. Budget Impact of Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia With Sustained Deep Molecular Response. Value in Health : 7 Mar 2021. Available from: URL: https://doi.org/10.1016/j.jval.2020.11.010
Rights and permissions
About this article
Cite this article
TKI discontinuation cost saving in patients with CML in remission. PharmacoEcon Outcomes News 874, 30 (2021). https://doi.org/10.1007/s40274-021-7573-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7573-7